CD19 and infection: The development of bi-specific CAR T cells capable of targeting both CD19 and BCMA aims to further enhance B-cell depletion and prevent antigen escape (69, 84), but likewise might further elevate the risk of severe infections due to profound B cell depletion and suppressed vaccine-induced immunity.